InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

InMed Pharmaceuticals' Finished Goods history runs 4 years deep, the most recent figure standing at $378636.0 for Q4 2025.

• On a quarterly basis, Finished Goods fell 43.92% year-over-year to $378636.0 in Q4 2025; TTM through Dec 2025 was $378636.0, a 43.92% decrease from a year earlier, with the FY2025 full-year figure at $676178.0, down 19.58% from the prior year.
• Finished Goods improved to $378636.0 in Q4 2025 per INM's latest filing, from $295809.0 in the prior quarter.
• Across five years, Finished Goods topped out at $927182.0 in Q3 2024 and bottomed at $231956.0 in Q1 2025.
• The 4-year median for Finished Goods is $582161.0 (2022), against an average of $596273.0.
• Across the five-year window, Finished Goods jumped 88.73% in 2023 and tumbled 68.1% in 2025, its largest moves.
• Year by year, Finished Goods stood at $605956.0 in 2022, then dropped by 7.94% to $557859.0 in 2023, then climbed by 21.03% to $675164.0 in 2024, then tumbled by 43.92% to $378636.0 in 2025.
• Per Business Quant, the three latest INM Finished Goods figures stand at $378636.0 (Q4 2025), $295809.0 (Q3 2025), and $676178.0 (Q2 2025).